To test whether RGS-induced anti-tumor effects are BRAFmut-specific or gender-dependent, we administrated RGS to female mice bearing NRASWTBRAFWT B16F10 tumors (Suppl.Fig. 2A), as well as to male mice bearing YUMM3.3 tumors (Suppl.Fig. 2B). The gene discussed is PITX2; the disease is neoplasm.